AE	Adverse Event
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
AUC	Area Under the Curve
BID	Twice Daily
Cmax	Maximum Plasma Concentration
CRC	Colorectal Cancer
CYP	Cytochrome P450
DLTs	Dose-Limiting Toxicities
ECOG PS	Eastern Cooperative Oncology Group Performance Status
EMT	Epithelial-to-Mesenchymal Transition
GAP	GTPase-Activating Protein
GDP	Guanosine Diphosphate
GEF	Guanine Nucleotide-Exchange Factor
GGT	Gamma-Glutamyl Transferase
GI	Gastrointestinal
GTP	Guanosine Triphosphate
HRAS	Harvey Rat Sarcoma
ILD	Interstitial Lung Disease
IV	Intravenous
KRAS	Kirsten Rat Sarcoma
mOS	Median Overall Survival
mPFS	Median Progression-Free Survival
MTD	Maximum Tolerated Dose
NA	Not Available
NCT	Clinical Trial Number
NRAS	Neuroblastoma Rat Sarcoma
NSCLC	Non-Small-Cell Lung Cancer
OA	Oral Administration
ORR	Objective Response Rate
OS	Overall Survival
PDAC	Pancreatic Ductal Adenocarcinoma
PD-L1	Programmed Death-Ligand 1
PFS	Progression-Free Survival
P-gp	P-Glycoprotein
PK	Pharmacokinetics
PPIs	Proton Pump Inhibitors
QD	Once Daily
QTc	Corrected QT Interval
RAS	Rat Sarcoma
T1/2	Half-Life
TEAE	Treatment-Emergent Adverse Event
TESAE	Treatment-Emergent Serious Adverse Event
Tmax	Time to Peak Concentration
TME	Tumor Microenvironment
TRAE	Treatment-Related Adverse Event
TRSAE	Treatment-Related Serious Adverse Event
Vd	Volume of Distribution